Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Exploring daratumumab as a treatment option for patients with T-ALL

Robin Foà • 11 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies CAR-T Daratumumab

In this video, Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses the results of a CAMPUS ALL study that evaluated the use of daratumumab for the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Prof. Foà first emphasizes the activity of this agent in patients with T-ALL and then goes on to explain the need for more trials in this disease area. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Robin Foà

5:14
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals